◈ Nootpedia
Compact view
Research pass: medium Compound WATCH-LIST HIGH

Metformin

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict WATCH-LIST HIGH

Strong longevity rationale in older / pre-diabetic adults (Barzilai TAME thesis), but for a 20yo metabolically healthy MMA athlete the case is weak: blunts exercise-induced mitochondrial biogenesis (Konopka 2019), no glycemic problem to fix, and B12 depletion is real on chronic use. Good compound, wrong stage of life. Reconsider after age 35-40 or if a future bloodwork shows insulin resistance.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    WATCH-LIST

    low priority. No metabolic problem to solve at 20 with normal HbA1c/HOMA-IR. Konopka/Walton exercise-blunting data is the strongest specific reason to skip — Dylan trains 10+ hr/week MMA + lifting, that's exactly the adaptation metformin attenuates. Reconsider at 35+ or if HbA1c drifts toward 5.7+, fasting insulin >7, HOMA-IR >2. Verdict: skip for V5; revisit annually or when bloodwork suggests metabolic drift.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    if metabolically marginal. Most relevant for desk-bound executives with HbA1c 5.5-5.9, mildly elevated fasting insulin, family history of T2D. Less compelling for already-fit lean executives without metabolic flags. Exercise-blunting still applies — if training hard, weigh accordingly.

  • 50+, mild cognitive decline / longevity-focus
    OPTIONAL-ADD

    to STRONG-CANDIDATE. This is the demographic the TAME trial is designed for. The risk-benefit shifts: metabolic decline is more likely, exercise adaptation matters less (relative to longevity), B12 supplementation is straightforward to manage. Once TAME reads out (~2027-2029), this verdict will firm up.

  • Anxiety-prone
    NEUTRAL

    No psychiatric effect.

  • High athletic load, tested status (WADA-tested)
    AVOID

    at intensity loads. Not on WADA banned list (legal), but Konopka/Walton mechanism is the wrong direction for any athlete optimizing training adaptation. If used at all, smallest dose, post-training timing.

  • Sleep-disordered
    NEUTRAL

    No direct sleep effect. Some users report reduced nocturia if pre-diabetic.

  • Recovery-focused (post-injury, post-illness)
    AVOID

    Anti-anabolic via mTOR inhibition is the wrong direction for tissue repair. Spermidine + autophagy is fine; metformin's mTOR inhibition is a different magnitude.

  • Strength/anabolic-focused
    AVOID

    Walton 2019 specifically shows blunted hypertrophy. Wrong tool.

▸ Subjective experience (deep)
  • Most users feel nothing acutely. Metformin is not a felt-effect compound at therapeutic doses.
  • GI side effects dominate the felt-experience profile — bloating, loose stools, occasional nausea. Mostly first 2-4 weeks; tapering up resolves it. Extended-release (Glucophage XR / Glumetza) cuts this dramatically.
  • Some active users report subjective exercise impairment — heart rate harder to climb, perceived exertion higher at given workload, slower recovery between intervals. This aligns with the Konopka/Walton mechanism data. Most relevant for endurance + hypertrophy training.
  • Mild appetite reduction (GLP-1 mediated) — modest, not a primary weight-loss drug at standard doses.
  • No mood, sleep, or cognitive felt effect at standard doses.
▸ Tolerance + cycling deep dive
  • Tolerance: Glycemic effect persists indefinitely; no pharmacological tolerance to AMPK pathway activation. Some adaptive downregulation theoretically possible but not clinically observed.
  • Cycling: Not standard practice. Daily continuous use is the clinical norm. Some longevity-community users cycle (e.g., 5 days on 2 off) to preserve exercise adaptation, but no evidence base for this.
  • Reset: Not applicable — discontinue and metabolic effects taper over days-weeks.
▸ Stacking deep dive

Synergistic with

  • berberine: Mechanistically overlapping (both AMPK activators). Stacking is redundant rather than additive. Pick one.
  • GLP-1 agonists (semaglutide, tirzepatide): Standard combination in T2D. Additive glycemic control. Different mechanisms.
  • Vitamin B12 (mandatory for long-term users): Methylcobalamin 1000mcg/day or hydroxocobalamin injections offset depletion. Non-negotiable on chronic metformin.
  • Methylfolate / B6: Offsets homocysteine elevation.
  • Acarbose, SGLT2i (empagliflozin): Different glycemic mechanisms; can stack.
  • Rapamycin (theoretical longevity stack): Both inhibit mTOR via different routes. Some longevity practitioners stack low-dose metformin with weekly rapamycin. No human outcome data.

Avoid stacking with

  • Iodinated contrast (radiology): Hold 48 hours pre/post for contrast CT due to lactic-acidosis risk via possible AKI.
  • Heavy alcohol: Increases lactic-acidosis risk via lactate buildup.
  • Sulfonylureas / insulin without monitoring: Hypoglycemia risk.
  • High-intensity endurance training programs (the athlete concern): Konopka/Walton data shows blunted training adaptation. Not a "dangerous" interaction but a meaningful counterproductive one for performance athletes.

Neutral / safe co-administration

  • All of Dylan's V4: NAC, citicoline, magnesium, fish oil, PS, rhodiola, theanine, glycine, vitamin D, curcumin, beta-alanine, vitamin C, creatine — all clean.
  • Modafinil, bromantane, Adamax/Semax, Selank, ALCAR, taurine, astaxanthin, tryptophan — all clean.
▸ Drug interactions deep dive
  • Cationic drugs sharing OCT2 transport (cimetidine, dolutegravir, ranolazine): Can raise metformin exposure ~40%. Usually manageable; flag for clinicians.
  • NSAIDs / ACE inhibitors / diuretics: All can reduce eGFR; combined use needs renal monitoring.
  • Topiramate, acetazolamide: Carbonic anhydrase inhibitors increase metabolic acidosis risk slightly.
  • Hormonal contraceptives: No interaction.
  • Most psychiatric meds: No interaction.
  • CYP enzymes: Metformin is not metabolized by CYP enzymes (excreted unchanged renally). No CYP-mediated interactions.
▸ Pharmacogenomics
  • OCT1 (SLC22A1) loss-of-function variants: Reduce hepatic uptake → reduced glycemic effect. ~25% of European-ancestry carry at least one reduced-function allele. Probably explains some of the responder/non-responder variability.
  • OCT2 (SLC22A2) variants: Affect renal clearance.
  • MATE1 variants: Affect biliary/renal excretion.
  • 23andMe → for Dylan: Once results land (~June 2026), OCT1 status is informative if metformin is ever considered. Not a deal-breaker, but moves the dose and expected efficacy.
  • No CYP polymorphism relevance (not CYP-metabolized).
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx PCP / endocrinologist $4-15/mo with insurance, ~$10-20 cash at Costco/Walmart high Generic glucophage extremely cheap. Off-label "longevity" Rx variable by physician.
US Rx (telehealth, longevity-positioned) AgelessRx, Modern Health Center, HoneCare-style $50-120/mo + visit fees high Longevity-leaning telehealth physicians are willing to Rx for healthy adults under aging-prevention framing.
Indian online pharmacy Same vendors used for modafinil (BuyModa, ModafinilXL adjacent listings) ~$15-30 for 90-day supply medium Generic glucophage. Fine for off-label use with COA. Dylan-comfortable sourcing channel.
Mexico OTC Pharmacies in border towns Cash, ~$5-15 medium Genuinely OTC there. Geographic constraint.

Recommendation for Dylan: Not currently sourcing — verdict is WATCH-LIST. If reconsidered post-bloodwork or post-30, AgelessRx-style telehealth or Indian generic is the path.

▸ Biomarkers to track (deep)
  • Baseline (before starting): HbA1c, fasting glucose, fasting insulin (calculate HOMA-IR), eGFR, creatinine, liver panel, vitamin B12, folate, homocysteine, lactate (if available).
  • During use: B12 + homocysteine annually (monthly first 3 months on novel use is overkill but reasonable on aggressive longevity protocols), HbA1c + lipids + eGFR annually, lactate if symptomatic. Subjective: GI tolerability, exercise capacity (perceived exertion + heart-rate response).
  • Post-cycle: Re-check fasting glucose and HbA1c if discontinued.
▸ Controversies / open debates Live debate

  • TAME hasn't read out. The single biggest open question. Until it does (anticipated 2027-2029), the "metformin extends healthy human lifespan" claim is a hypothesis, not an established fact.

  • Konopka/Walton exercise-blunting vs longevity benefit tradeoff. For metabolically healthy active adults, the data we have suggests metformin trades exercise adaptation for theoretical longevity benefit. This is exactly the wrong tradeoff for an MMA athlete optimizing performance.

  • Bannister "metformin > non-diabetics" finding. Provocative but confounded by immortal time bias and selection. Real signal magnitude is contested.

  • Cancer prevention claim. Mechanistically plausible (insulin reduction + AMPK + autophagy), epidemiologically suggestive in diabetics, but Mendelian randomization studies (using genetic variants in metformin's target as natural-experiment proxy) have been disappointing.

  • Berberine as natural alternative. Berberine activates AMPK via partially overlapping mechanism. Cheaper, OTC, fewer GI complaints in some users. Less validated in T2D RCTs but mechanism rationale similar. Choice between them is partly preference.

  • Generic vs extended-release. Glucophage XR/Glumetza dramatically reduces GI complaints at modest cost premium. Generic IR is cheapest but worst tolerated.

  • Phenformin-era reputation drag. Metformin's safety record is genuinely good, but older clinicians remain over-cautious about lactic acidosis based on phenformin's history. The actual numbers don't justify the lingering caution.

▸ Verdict change log
  • 2026-05-06 — Initial verdict: WATCH-LIST, HIGH confidence. Strong longevity rationale in older / metabolically-marginal adults; weak case for a 20yo healthy MMA athlete; Konopka/Walton exercise-adaptation blunting is the specific veto. Reconsider after 35-40, after TAME readout, or if Dylan's bloodwork (June 2026 baseline + annual) shows metabolic drift (HbA1c >5.7, fasting insulin >7, HOMA-IR >2).
▸ Open questions / gaps Open
  • TAME readout — most important.
  • Whether exercise-blunting magnitude is dose-dependent. Konopka used 1500mg/day; the longevity-community 500mg/day might preserve more adaptation. Untested.
  • Whether post-exercise timing avoids the blunting. Some have proposed metformin pre-bed only, sparing the AM/PM training window. Mechanistically plausible (peak plasma is brief), untested.
  • Effect in young metabolically healthy adults. Almost no data — every cohort study is in T2D or pre-diabetic populations.
  • Long-term cognitive trajectory. Mixed signals; B12 depletion confounds.
  • Microbiome-mediated benefit fraction. Increasingly clear part of the mechanism but not quantifiable per-user.
▸ Sources (full, with our context)
Back to compact view